PipelineFour algorithms · all research-stage

Pipeline

Each card states what the algorithm is for, its draft intended use, the stage it has actually reached, the regulatory pathway it is designed for, and the data it is built on.

Stages01 Research02 Retrospective validation03 Prospective study04 Regulatory
Retrospective research

NETRA

[Full name to be added]
[Clinical domain to be added]
Research
Retrospective validation
Prospective study
Regulatory
Indication
[Indication to be added]
Draft intended use
[Draft intended use to be added]
Target pathway
[Target pathway to be added]
Datasets
[Datasets to be added. Model card in preparation, pending the licence point.]
Data acquisition

CPI

CardioPredict-India
Cardiology · Cardiovascular risk
Research
Retrospective validation
Prospective study
Regulatory
Algorithm overview ↗
Indication
Cardiovascular risk in adults in India. Two modules: CPI-Primary (10-year risk of fatal and non-fatal MI and stroke, community and GP settings) and CPI-Acute (30-day major adverse cardiac events in chest-pain presentations).
Draft intended use
Intended to estimate cardiovascular risk as an aid to a clinician's own assessment, using variables specific to South Asian populations. Not intended to diagnose, or to replace clinical judgement.
Target pathway
CDSCO SaMD, Class B/C (target), followed by EU MDR and FDA pathways.
Datasets
CARRS and PURE India cohorts; CREATE and Kerala ACS registries; ICMR-INDIAB; WHO STEPS. Formal access requests follow company incorporation.
Data acquisition

INDIRA

Indian Breast Cancer Locoregional Recurrence Algorithm
Oncology · Breast cancer
Research
Retrospective validation
Prospective study
Regulatory
Algorithm overview ↗
Indication
Locoregional recurrence risk at 5 and 10 years in adults with non-metastatic breast cancer in India.
Draft intended use
Intended to estimate locoregional recurrence risk to inform the treating oncologist's discussion of adjuvant treatment. Not intended as a standalone basis for treatment decisions.
Target pathway
CDSCO SaMD, Class C (target).
Datasets
SEER 21 via SEER*Stat (proxy training, extraction in progress); individual patient data reconstructed from seven published Indian cohorts; ICGA (registration in progress); NCRP national incidence data.
Retrospective research

NFAD

NeuroFusion-AD
Neurology · Alzheimer's disease
Research
Retrospective validation
Prospective study
Regulatory
Algorithm overview ↗
Indication
Amyloid positivity and risk of cognitive decline in adults with mild cognitive impairment (MCI).
Draft intended use
Intended as non-autonomous clinical decision support, estimating risk to inform a clinician's decision on specialist referral. Not intended to diagnose Alzheimer's disease.
Target pathway
EU MDR, Class IIa SaMD (target).
Datasets
ADNI; Bio-Hermes-001; DementiaBank for final validation (access requires company incorporation, currently on hold).
Disclaimer

Every algorithm on this page is research software. None has been approved, cleared or CE-marked by CDSCO, an EU Notified Body, the FDA or any other regulator, and none is available for clinical use. Intended-use statements are drafts and will change as the research progresses. Device classes and pathways are design targets, not regulatory determinations. Nothing here is medical advice.